OMAHA, Neb., May 15 /PRNewswire/ -- Creighton Medical Laboratories, based at Creighton University School of Medicine in Omaha, announced today that it has become the first clinical laboratory worldwide to offer a new and more effective testing method for cancer.
The method, called SNP array karyotyping, has been successfully used in
research laboratories to study cancer for several years. However, Creighton Medical Laboratories, using AffymetrixTM SNP arrays, is the first laboratory to validate the test in a clinical setting and make it available for routine clinical use.
The method can help doctors make more accurate cancer diagnoses and tailor patient management based on the DNA profiles of each person's cancer.
Array-based karyotyping is a 21st century spin on older genetic testing methods that have helped guide patient care for decades. DNA is bundled inside cells as chromosomes; a karyotype is a representation of all of the chromosomes in a cell. Normal human cells have two copies of each
chromosome. Cancer cells will often duplicate or lose pieces of chromosomes, and these chromosomal changes can help physicians categorize a tumor, determine its aggressiveness, and/or determine which tumors will respond to specific drugs.
With the new method being used at Creighton Medical Laboratories, DNA from
tumor cells is applied to the arrays and scanned into a computer. The chromosomes are reconstructed by the computer to provide a genome-wide view of the cancer cells at unprecedented resolution; physicians then 'surf' the cancer genome using web-based genome browsers.
"SNP array karyotyping is a powerful new tool in our molecular tool box," said Jill Hagenkord, M.D., a pathologist and director of molecular pathology and clinical genomics at Creighton Medical Laboratories. "We can detect genetic abnormalities that previously would have been missed."
The SNP (single nucleotide polymorphism) array used by Creighton allows the detection of a very common genetic abnormality or lesion in cancer cells - called copy neutral loss of heterozygosity (LOH) - that often goes undetected with conventional diagnostic methods as well as standard array-based karyotyping.
"As an example, with SNP-array virtual karyotypes, we have detected copy neutral LOH at important regions of the cancer genome, like the p53 gene in chronic lymphocytic leukemia. If the tumor has no functional copies of this important gene, it tends to behave aggressively, and the treating physician may want to treat it more aggressively," Hagenkord said. "This genetic lesion would not have been detectable with the current testing methods, which really underscores the importance of having this new testing method available clinically."
Roger Brumback, M.D., chair of the Department of Pathology at Creighton University School of Medicine, said, "We feel that SNP array karyotyping will become the standard of care for the diagnosis and management of many cancers. Creighton Medical Laboratories is excited to be at the forefront of this technology and proud to provide progressive medical care for our patients."
"We are very fortunate to have Dr. Hagenkord at the helm in clinical genomics, since she is currently the only pathologist worldwide with fellowship training in both molecular genetic pathology and pathology/oncology informatics. She has been performing SNP array karyotyping of tumors since the technology emerged and she is truly an expert in the field."
For more information about the clinic, Hagenkord and SNP array karyotyping, visit http://cml.md.
About Creighton Medical Laboratories: (CML) is a leading provider of diagnostic medical testing and consultative services. Through its affiliation with Creighton University School of Medicine, an institution with an international reputation for medical research, CML helps physicians, clinics, nursing facilities and hospitals it serves deliver advanced and more effective patient-care.
About Creighton University: Creighton University, a Catholic, Jesuit institution located in Omaha, Neb., enrolls more than 4,000 undergraduate and 2,900 professional school and graduate students. Nationally recognized for providing a balanced educational experience, the University offers a rigorous academic agenda with a broad range of disciplines, providing undergraduate, graduate and professional degree programs that emphasize educating the whole person: academically, socially and spiritually. Creighton has been a top-ranked Midwestern university in the college edition of U.S. News & World Report magazine's for more than 20 years. For more information, visit our website at: www.creighton.edu.
This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.
Related medicine technology :1
. PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 20092
. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants3
. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit4
. Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimers Treatments5
. Tufts Medical Center Researchers Create a New Predictive Model for Age-related Macular Degeneration (AMD)6
. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer7
. PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)8
. Torax Medical Launches Pivotal Clinical Study of New Acid Reflux Treatment9
. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase10
. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting11
. Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial